Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Taxes (2023 - 2025)

Gyre Therapeutics (GYRE) has disclosed Change in Taxes for 3 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Taxes rose 187.1% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $318000.0, a 113.16% increase, with the full-year FY2023 number at $3.0 million, changed N/A from a year prior.
  • Change in Taxes was $1.5 million for Q3 2025 at Gyre Therapeutics, up from $513000.0 in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $2.5 million in Q3 2023 to a low of -$4.2 million in Q2 2024.
  • A 3-year average of $55500.0 and a median of $524000.0 in 2024 define the central range for Change in Taxes.
  • Biggest YoY gain for Change in Taxes was 187.1% in 2025; the steepest drop was 259.24% in 2025.
  • Gyre Therapeutics' Change in Taxes stood at -$185000.0 in 2023, then skyrocketed by 389.19% to $535000.0 in 2024, then soared by 187.1% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Change in Taxes are $1.5 million (Q3 2025), $513000.0 (Q2 2025), and -$2.3 million (Q1 2025).